)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Actinium Pharmaceuticals
Actinium Pharmaceuticals (ATNM) investor relations material
Actinium Pharmaceuticals Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy filing summary16 Oct, 2026
Executive summary
Annual Meeting scheduled for Nov. 25, 2026; stockholders of record on Oct. 2, 2026 may vote, with one vote per common share.
Board unanimously recommends FOR both director nominees, CBIZ auditor ratification and the advisory say-on-pay proposal.
Voting matters and shareholder proposals
David Nicholson and Richard I. Steinhart are nominees for Class I, three-year terms ending at the 2029 Annual Meeting; election is by plurality.
CBIZ CPAs P.C. appointment for FY ending Dec. 31, 2026 requires a majority of shares present and entitled to vote; abstentions and broker non-votes count against.
Say-on-pay covers NEO compensation for FY ended Dec. 31, 2025; approval requires a majority of shares present and entitled to vote, and broker non-votes have no effect.
Rule 14a-8 proposals for the 2027 meeting are due by June 17, 2027; director nominations for the proxy card under Rule 14a-19 are due by Sept. 26, 2027.
Board of directors and corporate governance
Six directors serve on a classified board; five are deemed independent under NYSE American standards.
Sandesh Seth combines Board Chair and CEO roles; David Nicholson serves as lead independent director and chairs independent-director executive sessions.
Board held six meetings in 2025; each director attended at least 75% of applicable Board and committee meetings.
Audit, Compensation, and Nominating and Corporate Governance committees are standing committees; committee chairs are independent directors.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Actinium Pharmaceuticals
- Positive SIERRA results position Iomab-B for a planned BLA, amid continued losses and a funded pipeline.ATNM
Q4 2022 - Higher R&D spend and losses, with Iomab-B’s 2024 BLA target central to the outlook.ATNMQ4 2023
- A differentiated Ac-225 pipeline approaches major 2026 clinical and translational readouts.ATNMInvestor presentation
- First-in-class radiotherapies advance toward pivotal trials and major market opportunities in 2026.ATNMInvestor presentation
- First-in-class radiotherapies advance toward pivotal data and commercialization in 2026.ATNMInvestor presentation
- Q2 2026 net income surged to $27.9M on $35M license revenue recognition; cash runway exceeds 12 months.ATNMQ2 2026
- First-in-class radiotherapies advance toward pivotal data and commercialization in 2026.ATNMInvestor presentation
- Multiple first-in-class radiotherapies advance toward key 2026 data, targeting major oncology markets.ATNMInvestor presentation
- Revitalized clinical pipeline and strong cash position drive new trials in AML, solid tumors, and prostate cancer.ATNM15th Annual LD Micro Invitational 2025
Next Actinium Pharmaceuticals earnings date
Q3 202620 Nov, 2026
Actinium Pharmaceuticals
Next Actinium Pharmaceuticals earnings date
Q3 202620 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development of targeted radiotherapies. These therapies are designed to deliver cancer-killing radiation to patients with high unmet medical needs, particularly in oncology and hematology. Actinium's lead product candidate, I-131 apamistamab (Iomab-B), is in a pivotal clinical trial targeting elderly patients with relapsed or refractory acute myeloid leukemia for bone marrow transplant conditioning. Actinium Pharmaceuticals Inc. is based in New York, New York, and its shares are listed on the NYSE.